Imfinzi (durvalumab) - AstraZeneca
Tecentriq (atezolizumab) - Roche
Opdivo (nivolumab) - Ono Pharmaceutical, BMS
Jemperli (dostarlimab-gxly) - GSK
Keytruda (pembrolizumab) - Merck (MSD)
Libtayo (cemiplimab-rwlc) - Regeneron
http://www.ncbi.nlm.nih.gov/pubmed/42809795
 
Bradley Switzer; Charmi Bhanushali; Pragya Jain; Sharanya Tripathi; Vidhi Bhanushali; Vidit Majmundar
 
Sep 30, 2026
 
Prev Next